Instrument Inactif

Autres langues Provectus Pharmaceuticals, Inc. OTC Bulletin Board

Actions

PVCT

US74373F1003

Recherche biotechnologique et médicale

Cours en clôture OTC Bulletin Board Autres places de cotation
- ^USD	-

18/05	Provectus Biopharmaceuticals fait état de l'activité antitumorale du PV-10 par voie orale dans une étude préclinique sur le cancer de la vessie	RE
18/05	Provectus Biopharmaceuticals fait état de l'activité antitumorale du PV-10 par voie orale dans une étude préclinique sur le cancer de la vessie	CI

Autres langues

08/06	Provectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of Stockholders
18/05	Provectus Biopharmaceuticals reports oral pv-10 anti-tumor activity in preclinical bladder cancer study
18/05	Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End
18/05	Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity In Preclinical Bladder Cancer Study
14/05	Provectus: Q1 Earnings Snapshot
14/05	Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
04/05	Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis
04/05	Provectus Biopharmaceuticals, Inc. Presents New Data on Rose Bengal Photodynamic Antimicrobial Therapy At Arvo 2026
21/04	Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee
02/04	Provectus Biopharmaceuticals Highlights Preclinical Evidence Of PV-10-Mediated Immune Modulation In Burn Wound Healing
02/04	Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment
26/03	Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
26/03	Provectus: Q4 Earnings Snapshot
26/03	Provectus Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
13/11	Provectus: Q3 Earnings Snapshot
13/11	Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
10/10/25	Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants, University of Calgary Research Highlights Novel STING-Pathway Activation
09/10/25	Provectus Biopharmaceuticals Positions Pv-10 as Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel Sting-Pathway Activation for Improving Hepatitis B Vaccine Efficacy
09/10/25	Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine Efficacy
29/09/25	Provectus Biopharmaceuticals initiates preclinical study of oral PV-10
29/09/25	Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer
29/09/25	Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer
14/08/25	Provectus: Q2 Earnings Snapshot
14/08/25	Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
17/07/25	Provectus Biopharmaceuticals, Inc. cancelled the transaction announced on July 17, 2024